story of the week
Effectiveness of Moderna, Pfizer-BioNTech, and Janssen Vaccines in Preventing COVID-19 Hospitalizations in Adults
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
MMWR. Morbidity and Mortality Weekly Report
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021
MMWR Morb. Mortal. Wkly. Rep. 2021 Sep 24;70(38)1337-1343, WH Self, MW Tenforde, JP Rhoads, M Gaglani, AA Ginde, DJ Douin, SM Olson, HK Talbot, JD Casey, NM Mohr, A Zepeski, T McNeal, S Ghamande, KW Gibbs, DC Files, DN Hager, A Shehu, ME Prekker, HL Erickson, MN Gong, A Mohamed, DJ Henning, JS Steingrub, ID Peltan, SM Brown, ET Martin, AS Monto, A Khan, CL Hough, LW Busse, CC Ten Lohuis, A Duggal, JG Wilson, AJ Gordon, N Qadir, SY Chang, C Mallow, C Rivas, HM Babcock, JH Kwon, MC Exline, N Halasa, JD Chappell, AS Lauring, CG Grijalva, TW Rice, ID Jones, WB Stubblefield, A Baughman, KN Womack, CJ Lindsell, KW Hart, Y Zhu, L Mills, SN Lester, MM Stumpf, EA Naioti, M Kobayashi, JR Verani, NJ Thornburg, MM PatelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.